Arrhythmias & electrophysiology
Polygenic Risk of New Onset Atrial Fibrillation in Nonischemic Cardiomyopathy
- cohort
- UK Biobank
+1 more
- UK Biobank
Authors' conclusion
PRSAF is a major risk factor for NOAF in NICM patients that can be used for AF risk stratification in conjunction with clinical risk factors.
Study context
- Population
- Participants with nonischemic cardiomyopathy (NICM) without prior atrial fibrillation (AF) diagnosisNICM cohort without prior AF diagnosis
- Participants
- 2,661 participants
- Exposure
- top 10th percentile of PRSAF risk compared with intermediate (10th to 89th percentile) risk participants
Main finding
As reported in the abstract
NOAF cases · median follow-up post-NICM diagnosis of 55 months (Q1-Q3: 19-113 months)
New onset atrial fibrillation (NOAF) cases
636 (23.9%)
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| NOAF · over 20 years of follow-up — top 10th percentile of PRSAF risk vs intermediate (10th to 89th percentile) risk | 1.91 (1.42–2.60) | |
| 0.20.5125Hazard ratio (log scale) |
| Outcome | HR per (SD 1.30) (95% CI) |
|---|---|
| NOAF · over 20 years of follow-up — PRSAF vs intermediate (10th to 89th percentile) risk | 1 (1.18–1.42) |
NOAF across CHARGE-AF categories; poor outcomes
- PRSAF predicted NOAF risk across all clinical risk (CHARGE-AF) categories but did not predict poor outcomes independent of NOAF status
Predictive performance
- integration of PRSAF into clinical risk stratification models significantly improved predictive performance
Original publication
Polygenic Risk of New Onset Atrial Fibrillation in Nonischemic Cardiomyopathy. JACC Clin Electrophysiol. Published 5 March 2026. doi:10.1016/j.jacep.2026.01.024
Summarised from the published abstract; every number is checked against it